Manufacturing

Fujifilm Diosynth To Expand Hillerød Facility, Adding 2,200 Jobs
Management & Regulatory Fujifilm Diosynth To Expand Hillerød Facility, Adding 2,200 Jobs

Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing

Private Equity Firms Acquire Avid Bioservices for $1.1 Billion
Management & Regulatory Private Equity Firms Acquire Avid Bioservices for $1.1 Billion

The biotechnology sector witnesses another strategic maneuver as private equity firms GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices for $1.1 billion. Avid, an influential contract development and manufacturing organization (CDMO), specializes in

Revolutionizing Biomanufacturing: Real-Time Analytics with Laser Force Cytology
Management & Regulatory Revolutionizing Biomanufacturing: Real-Time Analytics with Laser Force Cytology

In today's rapidly evolving field of biomanufacturing, traditional methods often fall short of the rigorous demands for real-time data and consistent product quality. Laser Force Cytology (LFC) has emerged as an innovative, label-free technology that offers a transformative approach to

How Is Celltrion Expanding Zymfentra Access for US Patients?
Management & Regulatory How Is Celltrion Expanding Zymfentra Access for US Patients?

In recent developments, Celltrion USA has significantly expanded the availability of its subcutaneous treatment for Crohn's disease and ulcerative colitis, Zymfentra, now accessible to 26 million patients across the United States. This milestone achievement is a result of the company’s s

How Will Sterling Pharma's £10M Investment Boost ADC Capacity?
Management & Regulatory How Will Sterling Pharma's £10M Investment Boost ADC Capacity?

Sterling Pharma Solutions is significantly expanding its GMP antibody-drug conjugate (ADC) manufacturing capacity with a £10 million investment aimed at doubling the current capacity at its Deeside, UK site. This expansion involves commissioning a new 2,300-square-foot suite, which includes a

How Will MilliporeSigma's $76M Expansion Impact Cancer Treatment?
Management & Regulatory How Will MilliporeSigma's $76M Expansion Impact Cancer Treatment?

MilliporeSigma has announced a substantial $76 million investment to expand its Bioconjugation Center of Excellence in St. Louis, Missouri, aiming to triple its current capacity for Antibody-Drug Conjugates (ADCs). This significant expansion will encompass upgrading 34,000 square feet of existing

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later